key: cord-0785502-gpq93etq authors: Barbeta, Enric; Benegas, Mariana; Sánchez, Marcelo; Motos, Anna; Ferrer, Miquel; Ceccato, Adrián; Lopez, Rubén; Bueno, Leticia; -Artigas, Ricard Mellado; Ferrando, Carlos; Fernández-Barat, Laia; Albacar, Nuria; Badia, Joan Ramon; López, Teresa; Sandoval, Elena; Toapanta, David; Castro, Pedro; Soriano, Alex; Torres, Antoni title: Factores de riesgo e impacto clínico de los cambios fibróticos y el patrón de neumonía organizada en los pacientes con síndrome de distrés respiratorio agudo producido o no por COVID-19 date: 2021-06-04 journal: Arch Bronconeumol DOI: 10.1016/j.arbres.2021.05.023 sha: a88622d2086f7520b5757b188c15f5424977bdad doc_id: 785502 cord_uid: gpq93etq nan The study was approved by the Institution's Internal Review Board (HCB/2018/0231) Informed written consent was obtained from the patients for publication of this article. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. I declare no competing interests. Patients with COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) face high mortality due primarily to respiratory failure. [1] [2] [3] [4] Diffuse alveolar damage (DAD)-the most common histological finding in these patients-can develop into a fibroproliferative phase and increase mortality risk. 5, 6 In several COVID-19 autopsy reports, the presence of DAD and a pattern of acute fibrinous organizing pneumonia have been identified. 7 Organizing pneumonia is a manifestation of acute lung injury, which can be found in isolation or accompanying other lung diseases such as DAD. Organizing pneumonia is known to be able to develop into interstitial fibrosis and increase mortality risk as well, but it is often responsive to steroids. 8, 9 Currently, it remains unknown as to whether patients with COVID-19-induced ARDS, in comparison to those with non-COVID-19-induced ARDS, have slower or defective resolution of pulmonary inflammation characterized by interstitial abnormalities such as fibrotic-like changes and/or organizing pneumonia. Therefore, we will evaluate the presence of persistent or new-onset diffuse pulmonary opacities in these patients, as well as fibrotic-like changes with or without an organizing pneumonia pattern within the first week of ARDS diagnosis. Finally, in patients with COVID-19, we will analyze risk factors associated with the presence of fibrotic-like changes, and determine any possible association between these findings and clinical outcomes. We included all consecutive patients admitted to our institution for COVID-19-and non-COVID-19-induced ARDS 10 between June 15 th , 2019 and March 28 th , 2020. Patients who presented with one of the following criteria were excluded from the study: mechanical ventilation >72 hours before inclusion; PaO2/FiO2 >300 within 24 hours of inclusion; expected decisions to have life-sustaining treatment withdrawn in <24 hours; refusal of study participation on behalf of relatives; and the presence of previously known interstitial lung 7 disease. Patients were divided into two groups according to the cause of ARDS (i.e., COVID-19 and non-COVID-19 cohorts). We compared the presence of persistent or new-onset diffuse pulmonary opacities in chest xrays (CXRs) beginning day 7 of ARDS diagnosis to death or intensive care unit (ICU) discharge. Furthermore, we assessed the presence and severity of pulmonary fibrotic-like changes and organizing pneumonia pattern in thoracic computed tomography (CT) scans during the same time frame. Patients with COVID-19-related ARDS were further divided into those who presented with fibrotic-like changes and those who did not. We analyzed risk factors for its development and compared clinical outcomes between both groups. Attending doctors ordered thoracic CT scans without following any research protocol. Time (days) from ARDS diagnosis to CT scan was recorded. CXRs were performed every 24 to 48 hours per protocol until ICU discharge. A pulmonologist and experienced thoracic radiologist independently and blindly assessed CT features to diagnose fibrotic-like changes and organizing pneumonia pattern. Additionally, two pulmonologists independently and blindly assessed CXRs to diagnose persistent or new-onset diffuse pulmonary opacities. Agreement between evaluators was assessed for CT scans and CXRs using Cohen's Kappa. After the first independent analysis, and without unblinding the cohort, evaluators met to discuss the radiological images on which there was a disagreement. Persistent or new onset diffuse pulmonary opacities were defined as the presence of any of the following criteria between day 7 since ARDS diagnosis and death or ICU discharge: 1) persistence of ≥ 50% of radiological opacities found at ARDS diagnosis 2) an increase in or new-onset bilateral pulmonary opacities between day 7 since ARDS diagnosis and death or ICU discharge. An increase in radiological opacities had to be identified in both lungs. Newonset unilateral opacities did not meet this definition. Fibrotic-like changes were defined as the presence of traction bronchiectasis, reticulation, parenchymal bands and/or honeycombing in thoracic CT scans performed between day 7 since ARDS diagnosis and death or ICU discharge. 11 Extension of fibrotic-like changes in thoracic CT scans was classified into one of three categories based on visual assessment and the percentage of bilateral lung involvement: mild (< 25%), moderate (25-50%) and severe (>50%). An organizing pneumonia pattern was defined as peribronchovascular consolidations with perilobular distribution and/or the reverse halo sign between day 7 since ARDS diagnosis and death or ICU discharge. 11 Further, in the same manner, we assessed 30-and 90-day, hospital and ICU mortality, as well Figure 1) . Of the 101 patients included in the analysis, 81 had sequential CXRs beginning day 7 since ARDS diagnosis to death or ICU discharge. In addition, and within the same time frame, fifty patients underwent a thoracic CT scan. Table 1 shows the demographic and clinical characteristics of these patients. Patients with COVID-19-induced ARDS (n= 24, 71%) presented with a higher incidence of fibrotic-like changes when compared to those with non-COVID-19-induced ARDS (n = 2, 12%) (p = 0.001). All patients with COVID-19 and fibrotic-like changes also presented with an organizing pneumonia pattern in thoracic CT scans. With respect to assessments of CT scan features, agreement between the thoracic radiologist and pulmonologist was 0.64; regarding assessments of CXRs, agreement between pulmonologists was 0.73. Table 2 and Supplementary Table 1 show the characteristics of patients with COVID-19- induced ARDS, presenting with or without fibrotic-like changes. Those patients who later developed fibrotic-like changes or an extensive manifestation of these changes had higher dead space (ventilatory ratio) on day 3 since the ARDS diagnosis. In addition, we more frequently identified ventilation with higher tidal volume and positive end-inspiratory pressure upon ARDS diagnosis in patients who later presented with fibrotic-like changes or its extensive manifestation, respectively. Likewise, administering mechanical ventilation with a higher tidal volume and driving pressure on day 3 since ARDS diagnosis was associated The main findings of this study are the following: first, patients with COVID-19-induced ARDS more frequently presented with fibrotic-like changes and an organizing pneumonia pattern than those with non-COVID-19-induced ARDS. Second, higher dead space ventilation (i.e., ventilatory ratio), tidal volume, end-inspiratory pressure and driving pressure during the early course of ARDS were associated with the development of fibrotic-like changes in patients with COVID-19-induced ARDS. Finally, the manifestation of fibroticlike changes in its extensive form occurred in 36% of patients, being associated with longer mechanical ventilation and ICU length of stay. Pulmonary fibrotic-like changes are a radiological manifestation of a defective healing process of the lung, which is related to higher mortality. 12, 13 As in ARDS caused by other risk factors, exudative or fibroproliferative DAD is already known to be the main histological pattern in COVID-19-induced ARDS. 14 In our study, we identified an organizing pneumonia pattern in all patients with COVID-19 who also presented with fibrotic-like changes. The fact that DAD can have regions with organizing pneumonia or acute fibrinous organizing pneumonia has been well-established. 14 However, it remains unknown as to whether COVID-19-induced ARDS includes larger lung areas of these two histological patterns (organizing pneumonia or acute fibrinous organizing pneumonia). Our findings raise concerns about whether SARS-CoV-2 more frequently elicits a transition from inflammation to an organizing process. Further, our findings invite the consideration of whether steroids would confer a benefit even if DAD is present as well. We found that, during the early course of ARDS, several variables related to VILI (i.e., tidal volume, positive end-inspiratory pressure and driving pressure) were associated with the development of fibrotic-like changes. Interestingly, this association was identified even when all of these parameters were within the range that is currently believed to be protective. The degree of impairment in oxygenation at days 1 and 3 since ARDS diagnosis was not related to the development of fibrotic-like changes. Conversely, on day 3, higher dead space ventilation was found in patients who developed extensive and non-extensive fibrotic-like changes. In comparison to oxygenation, dead space ventilation is a better marker of lung inhomogeneities and is strongly related to a higher mortality risk. 15 This study has several limitations. First, due to the observational design of the study, there was no specific protocol to perform CT scans. A selection bias may therefore have diagnosis, and information provided by CT scans should be interpreted with caution Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Clinical characteristics of 82 cases of death from COVID-19 Causes of mortality in patients with the adult respiratory distress syndrome Frutos-Vivar F. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage Cryptogenic organising pneumonia ARDS Definition Task Force Acute respiratory distress syndrome: the Berlin Definition Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia Fibroproliferative changes on high-resolution CT in the acute respiratory distress syndrome predict mortality and ventilator dependency: a prospective observational cohort study Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza Lung inhomogeneity in patients with acute respiratory distress syndrome We would like to thank Anthony Armenta for providing medical editing assistance for the article at hand. The Covid Clinic Critical Care Group*. Epidemiology, clinical characteristics, radiology and microbiology of 101 patients with ARDS, presenting with or without COVID-19.